
UK health watchdog rejects gene therapy for haemophilia B
In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted a marketing authorisation by the UK Medicines… Read More













